Drug Shortage Report for SODIUM CHLORIDE INJECTION, USP

Last updated on 2023-02-09 History
Report ID 170965
Drug Identification Number 02139510
Brand name SODIUM CHLORIDE INJECTION, USP
Common or Proper name SODIUM CHLORIDE INJECTION, USP
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) SODIUM CHLORIDE
Strength(s) 234MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 100mL
ATC code B05XA
ATC description I.V. SOLUTION ADDITIVES
Reason for shortage Other (Please describe in comments)
Anticipated start date 2022-10-04
Actual start date 2022-10-04
Estimated end date 2023-02-01
Actual end date 2023-01-31
Shortage status Resolved
Updated date 2023-02-09
Company comments Effective January 1, 2023, allocations for our Sodium Chloride Injection, USP 4 mmol/mL PBP Vial 100 mL will be increased to cover the 200 mL backorder. Contract customers will be allocated 100% of historical 100 mL demand plus 100% of historical 200 mL demand at a 2:1 ratio (2 vial of 100 mL = 1 vial of 200 mL), and 100% of historical 30 mL demand at a 1:2 ratio (1 vial of 100 mL = 2 vials of 30 mL).
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v9 2023-02-09 French Compare
v8 2023-02-09 English Compare
v7 2023-01-02 French Compare
v6 2023-01-02 English Compare
v5 2022-12-05 French Compare
v4 2022-12-05 English Compare
v3 2022-10-05 English Compare
v2 2022-10-03 French Compare
v1 2022-10-03 English Compare

Showing 1 to 9 of 9